Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN
Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.
Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.
For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.
Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).
Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.
An analysis suggested that a shorter, 3-month course of adjuvant chemotherapy for some patients with stage III colon cancer may yield comparable outcomes to the standard 6-month course.
Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.